Form 4: Serina Therapeutics Director Granted Stock Options

Serina Therapeutics director Stephen K. Brannan was granted 10,000 stock options with an exercise price of $3.91.

Summary

• Stephen K. Brannan, a Director of Serina Therapeutics, Inc. (SER), was granted 10,000 stock options.
• The transaction date for this grant was November 7, 2025.
• Each stock option has an exercise price of $3.91.
• The options will vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date (November 7, 2026), contingent on Mr. Brannan's continued service.
• The expiration date for these stock options is November 7, 2035.
• Following this transaction, Mr. Brannan beneficially owns 10,000 derivative securities directly.

Sentiment

Score: 6

Explanation: Slightly positive, as the grant of stock options to a director generally indicates an effort to align management incentives with shareholder interests, which is a positive governance practice. However, it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Negatives

• The issuance of new stock options could lead to minor potential dilution for existing shareholders if exercised, though 10,000 options is a relatively small amount.

Risks

• The value of the stock options is contingent on the company's stock price exceeding the exercise price of $3.91; if the stock price remains below this, the options may expire worthless.
• The options are subject to forfeiture if the reporting person's service to the Issuer ceases before the vesting conditions are met.

Future Outlook

The stock options are designed to incentivize the director's continued service and align their interests with the company's long-term performance, with vesting contingent on future service and an expiration date ten years from the grant.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, as well as other sectors, to attract, retain, and motivate key personnel by linking their compensation to the company's stock performance. This aligns management and board interests with shareholder value creation.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to foster long-term commitment and performance alignment.
• The vesting schedule, tied to continued service and an annual meeting, is typical for such equity grants, ensuring the director's ongoing engagement.
• An exercise price set at the market price on the grant date (implied by the nature of a standard option grant) is also a common industry practice.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also potential for increased long-term value creation due to aligned director incentives.
• Employees: No direct impact mentioned, but part of broader compensation strategies that can influence company culture and talent retention.

Next Steps

• The stock options will vest on the earlier of the day before the next Annual Meeting or November 7, 2026, subject to continued service.

Key Dates

Keywords

Serina Therapeutics, SER, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant, Beneficial Ownership